Alteration of lymphocyte function by quinones through a sulfhydryl-dependent disruption of microtubule assembly.
The cytoskeleton plays a pivotal role in lectin-induced lymphocyte blastogenesis. Microtubule disrupting agents, many of which are sulfhydryl (SH) reagents, interfere with cytoskeletal-dependent cell functions including lymphocyte blastogenesis and agglutination. For example, hydroquinone (HQ) and N-ethylmaleimide (NEM) inhibit lectin-stimulated lymphocyte blastogenesis and agglutination at concentrations (10(-5)M) that do not reduce cell viability or ATP production. Indicative of the SH-specificity of these effects, only L-cysteine protects against HQ or NEM inhibition of blastogenesis and agglutination. Other compounds, including L-serine, DL-lysine and imidazole, have no protective effect. These and other findings previously reported suggest a selective interaction of HQ, or its oxidation product, p-benzoquinone (p-BQ) with SH groups critical to early G1 events associated with lymphocyte activation. These compounds show similar SH specificity in inhibiting microtubule assembly in vitro. The subcellular target specificity (cytoskeleton) exhibited by these compounds was compared to that of Adriamycin (ADR), a complex polycyclic quinone with known immunotoxic activity. ADR inhibited microtubule assembly in vitro and inhibited lymphocyte blastogenesis, however, these effects were not correlated with a loss of agglutination nor was toxicity protected against by the addition of SH compounds. The combination of cell culture methods together with application of techniques to measure microtubule assembly in vitro provides an effective means to discriminate between agents that selectively interfere with cytoskeletal-dependent function and those producing non-specific effects associated with cell death, such as decreased energy production or increased membrane permeability.
D000371:Agglutination / Q000187:drug effects; D016227:Benzoquinones; D004317:Doxorubicin / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D008870:Microtubules / Q000187:drug effects*; D011485:Protein Binding / Q000187:drug effects; D011809:Quinones / Q000494:pharmacology*; D013438:Sulfhydryl Compounds / Q000494:pharmacology; D014404:Tubulin / Q000378:metabolism*
D016227:Benzoquinones; D011809:Quinones; D013438:Sulfhydryl Compounds; D014404:Tubulin; C004532:quinone; D004317:Doxorubicin